<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer Milan</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21915651</article-id><article-id pub-id-type="pmc">3208033</article-id><article-id pub-id-type="publisher-id">381</article-id><article-id pub-id-type="doi">10.1007/s10194-011-0381-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Suggested randomised, controlled trial with frovatriptan</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tfelt-Hansen</surname><given-names>Peer</given-names></name><address><email>d036218@dadlnet.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Steiner</surname><given-names>Timothy J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Danish Headache Center, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark </aff><aff id="Aff2"><label>2</label>Norwegian Headache Centre, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>9</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>9</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2011</year></pub-date><volume>12</volume><issue>6</issue><fpage>665</fpage><lpage>666</lpage><history><date date-type="received"><day>11</day><month>8</month><year>2011</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2011</copyright-statement></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Sir,</p><p><bold>Frovatriptan versus other treatments for acute migraine</bold></p><p>There are now three crossover, double-blind, randomized controlled trials (RCTs) of similar design comparing frovatriptan 2.5&#x000a0;mg with zolmitriptan 2.5&#x000a0;mg [<xref ref-type="bibr" rid="CR1">1</xref>], rizatriptan 10&#x000a0;mg [<xref ref-type="bibr" rid="CR2">2</xref>] and almotriptan 12.5&#x000a0;mg [<xref ref-type="bibr" rid="CR3">3</xref>]. Each RCT found no significant differences between the treatments with regard to patients&#x02019; expressed preferences and, as secondary outcome measures, the conventional end-points of pain-freedom and headache relief [<xref ref-type="bibr" rid="CR4">4</xref>]. A meta-analysis of the three trials, all without placebo comparison, found them to be the sufficient evidence of equal efficacy of frovatriptan and these other triptans [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>Is this useful knowledge? There appears to be a consensus supporting head-to-head comparisons between triptans as the evidential basis for selecting best treatment. Clinical experience, which is not easily converted into formal evidence, nonetheless demonstrates that differences between triptans at group level are generally less influential than the differences in individual responses to them. So, in practice, those for whom triptans are indicated will still need to make their own comparative assessments.</p><p>The prior question is: for whom are triptans indicated? Accordingly, one important comparative RCT is missing. Effervescent aspirin 1,000&#x000a0;mg was quite similar to sumatriptan 50&#x000a0;mg in the treatment of migraine attacks in a meta-analysis of three RCTs [<xref ref-type="bibr" rid="CR6">6</xref>]. The World Health Organization currently advocates only aspirin or paracetamol as treatments for acute migraine in adults [<xref ref-type="bibr" rid="CR7">7</xref>]. It would be of great help to people with migraine worldwide if triptans were shown to be superior to aspirin.</p><p>The clinically relevant RCT is therefore frovatriptan 2.5&#x000a0;mg versus effervescent aspirin 1,000&#x000a0;mg with the crossover design and, ideally, placebo control [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Yours sincerely</p><p>Peer Tfelt-Hansen, MD, DMSc</p><p>Timothy J Steiner, MB, PhD, LLM</p></body><back><ack><title>Conflict of interest</title><p>None.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tullo</surname><given-names>V</given-names></name><name><surname>Allais</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Curone</surname><given-names>M</given-names></name><name><surname>Mea</surname><given-names>E</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Benedetto</surname><given-names>C</given-names></name><name><surname>Zava</surname><given-names>D</given-names></name><name><surname>Bussone</surname><given-names>G</given-names></name></person-group><article-title>Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study</article-title><source>Neurol Sci</source><year>2010</year><volume>31</volume><issue>Suppl 1</issue><fpage>S51</fpage><lpage>S54</lpage><pub-id pub-id-type="doi">10.1007/s10072-010-0273-x</pub-id><pub-id pub-id-type="pmid">20464583</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savi</surname><given-names>L</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Lisotto</surname><given-names>C</given-names></name><name><surname>Zanchin</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Zava</surname><given-names>D</given-names></name><name><surname>Pinessi</surname><given-names>L</given-names></name></person-group><article-title>A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine</article-title><source>J Headache Pain</source><year>2011</year><volume>12</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1007/s10194-010-0243-y</pub-id><pub-id pub-id-type="pmid">20686810</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolini</surname><given-names>M</given-names></name><name><surname>Giamberardino</surname><given-names>MA</given-names></name><name><surname>Lisotto</surname><given-names>C</given-names></name><name><surname>Martelletti</surname><given-names>P</given-names></name><name><surname>Moscato</surname><given-names>D</given-names></name><name><surname>Panascia</surname><given-names>B</given-names></name><name><surname>Savi</surname><given-names>L</given-names></name><name><surname>Pini</surname><given-names>LA</given-names></name><name><surname>Sances</surname><given-names>G</given-names></name><name><surname>Santoro</surname><given-names>P</given-names></name><name><surname>Zanchin</surname><given-names>G</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Brighina</surname><given-names>F</given-names></name><name><surname>Fierro</surname><given-names>B</given-names></name></person-group><article-title>A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine</article-title><source>J Headache Pain</source><year>2011</year><volume>12</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1007/s10194-011-0325-5</pub-id><pub-id pub-id-type="pmid">21437714</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">International Headache Society Clinical Trials Subcommittee (2000). Guidelines for controlled trials of drugs in migraine, 2nd edn. Cephalalgia 20:765&#x02013;786</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortelli</surname><given-names>P</given-names></name><name><surname>Allais</surname><given-names>G</given-names></name><name><surname>Tullo</surname><given-names>V</given-names></name><name><surname>Benedetto</surname><given-names>C</given-names></name><name><surname>Zava</surname><given-names>D</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Bussone</surname><given-names>G</given-names></name></person-group><article-title>Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies</article-title><source>Neurol Sci</source><year>2011</year><volume>32</volume><issue>Suppl 1</issue><fpage>S95</fpage><lpage>S98</lpage><pub-id pub-id-type="doi">10.1007/s10072-011-0551-2</pub-id><pub-id pub-id-type="pmid">21533722</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampl</surname><given-names>C</given-names></name><name><surname>Voelker</surname><given-names>M</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name></person-group><article-title>Efficacy and safety of 1,000&#x000a0;mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms</article-title><source>J Neurol</source><year>2007</year><volume>254</volume><fpage>705</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1007/s00415-007-0547-2</pub-id><pub-id pub-id-type="pmid">17406776</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">World Health Organization (2010) WHO model list of essential medicines, 16th list. WHO, Geneva. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_list_en.pdf">http://www.who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_list_en.pdf</ext-link></mixed-citation></ref></ref-list></back></article>